A Retrospective Comparative Study between Levosimendan and Adrenaline as a Pharmacological Protocol for the Management of Coronary Artery Bypass Grafting Patients with Low Ejection Fraction: A Friend or Foe
Background: Left ventricular ejection fraction is an independent determinant of the outcome of coronary artery bypass surgery. Low preoperative ejection fraction requires special care in terms of pharmacological and mechanical inotropic support. Adrenaline is the most widely used inotropic drug, while levosimendan is a relatively new inotropic drug in the field of cardiac surgery. In this study, we aimed to evaluate the relative efficacy of levosimendan in low ejection fraction patients undergoing coronary artery bypass grafting (CABG). Methods: A retrospective comparative study was performed with 63 patients who underwent isolated on-pump elective CABG with a preoperative ejection fraction below 40%. Patients were allocated to the adrenaline group (n = 35) and levosimendan group (n = 28). Patients were further stratified according to ejection fraction above 30% and below or equal to 30%. The primary outcome was cardiac-related mortality, while other parameters were considered secondary endpoints. Results: EuroSCORE of the adrenaline group was 3.34 ± 1.26 and for the levosimendan group 3.15 ± 1.42 (p value 0.576). Nine patients of the adrenaline group had new postoperative atrial fibrillation compared to seven patients in the levosimendan group (p value 0.948). Two patients of the adrenaline group had postoperative ventricular arrhythmia compared to only one patient in the other group (p value 0.691). The adrenaline group had higher doses of inotropic support compared to the levosimendan group 210.84 ± 23.74 and 157.4 ± 22.69 ng/kg/min respectively (p value < 0.001). Longer ventilation hours and overall duration of ICU stay were also noticed in the adrenaline group 32.57 ± 7.23 hours, 8.84 ± 3.28 days in comparison to the levosimendan group 24.37 ± 5.09 hours, 6.23 ± 2.37 days (p values < 0.001 and 0.002 respectively). However, the primary endpoint was not significantly different between the two groups. Conclusions: The levosimendan-based protocol failed to improve overall mortality in low ejection fraction patients undergoing CABG. However, this protocol significantly reduced the dose of inotropic and vasoconstrictor support needed, ventilation hours and duration of ICU stay.
References
[1]
Diodato, M. and Chedrawy, E.G. (2014) Coronary Artery Bypass Graft Surgery: The Past, Present, and Future of Myocardial Revascularisation. Surgery Research and Practice, 2014, 1-6. https://doi.org/10.1155/2014/726158
[2]
Cesar, L.A.M. and Viana, C.B. (2014) Strategy for Therapeutic Decision Medical vs. Angioplasty vs. Surgery. Revista da Sociedade de Cardiologia do Estado de São Paulo, 24, 17-22.
[3]
Kamal, Y.A., Al-Elwany, S.E., Ghoneim, A.M. and El-Minshawy, A.M. (2017) Predictors of Adverse Effects after Coronary Artery Bypass Grafting in Patients with Reduced Left Ventricular Ejection Fraction. Journal of the Egyptian Society of Cardio-Thoracic Surgery, 25, 20-27. https://doi.org/10.1016/j.jescts.2017.02.002
[4]
Deppe, A.-C., Weber, C., Liakopoulos, O.J., et al. (2017) Preoperative Intra-Aortic Balloon Pump Use in High-Risk Patients Prior to Coronary Artery Bypass Graft Surgery Decreases the Risk for Morbidity and Mortality—A Meta-Analysis of 9,212 Patients. Journal of Cardiac Surgery, 32, 177-185. https://doi.org/10.1111/jocs.13114
[5]
Ibanez, B., James, S., Agewall, S., Antunes, M.J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A.L.P., Crea, F., Goudevenos, J.A., Halvorsen, S., Hindricks, G., Kastrati, A., Lenzen, M.J., Prescott, E., Roffi, M., Valgimigli, M., Varenhorst, C., Vranckx, P. and Widimsky, P. (2017) ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation: The Task Force for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal, ehx393.
[6]
Hamad, M.A.S., Straten, A.H.V., Schönberger, J.P., et al. (2010) Preoperative Ejection Fraction as a Predictor of Survival after Coronary Artery Bypass Grafting: Comparison with a Matched General Population. Journal of Cardiothoracic Surgery, 5.
[7]
Pieri, M., Belletti, A., Monaco, F., et al. (2016) Outcome of Cardiac Surgery in Patients with Low Preoperative Ejection Fraction. BMC Anesthesiology, 16.
https://doi.org/10.1186/s12871-016-0271-5
[8]
Berry, W. and McKenzie, C. Use of Inotropes in Critical Care. Pharmaceutical Journal.
https://www.pharmaceutical-journal.com/learning/learning-article/use-of-inotropes-in-critical-care/11049283.article
[9]
Dickstein, K. (2008) ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008: Application of Natriuretic Peptides: Reply. European Heart Journal, 30, 383. https://doi.org/10.1093/eurheartj/ehn561
[10]
Ukkonen, H. (2000) Myocardial Efficiency during Levosimendan Infusion in Congestive Heart Failure. Clinical Pharmacology & Therapeutics, 68, 522-531.
https://doi.org/10.1067/mcp.2000.110972
[11]
Rungatscher, A., Linardi, D., Tessari, M., et al. (2012) Levosimendan Is Superior to Epinephrine in Improving Myocardial Function after Cardiopulmonary Bypass with Deep Hypothermic Circulatory Arrest in Rats. The Journal of Thoracic and Cardiovascular Surgery, 143, 209-214. https://doi.org/10.1016/j.jtcvs.2011.09.020
[12]
Lilleberg, J., Nieminen, M.S., Akkila, J., Heikkila, L., Kuitunen, A. and Lehtonen, L. (1998) Effects of a New Calcium Sensitizer Levosimendan on Haemodynamics, Coronary Blood Flow and Myocardial Substrate Utilization Early after Coronary Artery Bypass Grafting. European Heart Journal, 19, 660-668.
https://doi.org/10.1053/euhj.1997.0806
[13]
Nijhawan, N., Nicolosi, A.C., Montgomery, M.W., Aggarwal, A., Pagel, P.S. and Warltier, D.C. (1999) Levosimendan Enhances Cardiac Performance after Cardiopulmonary Bypass: A Prospective, Randomized Placebo-Controlled Trial. Journal of Cardiovascular Pharmacology, 34, 219-228.
https://doi.org/10.1097/00005344-199908000-00007
[14]
Rajek, A.M., Koinig, H., Jelen, M., Schiferer, A. and Hutschala, D. (2003) Levosimendan, a New Ca-Sensitizer, in Patients with Poor Left Ventricular Function Undergoing Cardiac Surgery. Anesthesiology, 99, A133.
[15]
Raja, S.G. and Rayen, B.S. (2006) Levosimendan in Cardiac Surgery: Current Best Available Evidence. The Annals of Thoracic Surgery, 81, 1536-1546.
https://doi.org/10.1016/j.athoracsur.2005.08.073
[16]
Sanfilippo, F., Knight, J.B., Scolletta, S., et al. (2017) Levosimendan for Patients with Severely Reduced Left Ventricular Systolic Function and/or Low Cardiac Output Syndrome Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis. Critical Care, 21, 252. https://doi.org/10.1186/s13054-017-1849-0
[17]
Eris, C., Yavuz, S., Toktas, F., Turk, T., Gucu, A., Erdolu, B. and Goncu, M.T. (2014) Preoperative Usages of Levosimendan in Patients Undergoing Coronary Artery Bypass Grafting. International Journal of Clinical and Experimental Medicine, 7, 219-229.
[18]
Tritapepe, L., Santis, V.D., Vitale, D., et al. (2009) Levosimendan Pre-Treatment Improves Outcomes in Patients Undergoing Coronary Artery Bypass Graft Surgery. British Journal of Anaesthesia, 102, 198-204. https://doi.org/10.1093/bja/aen367
[19]
Nenna, A., Greco, S.M., Barbato, R. and Chello, M. (2017) Levosimendan in Cardiac Surgery: Is It All Gold That Glitters? Journal of Cardiovascular Diseases & Diagnosis, 5, 276. https://doi.org/10.4172/2329-9517.1000276
[20]
Mehta, R.H., Leimberger, J.D., Diepen, S.V., et al. (2017) Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. New England Journal of Medicine, 376, 2032-2042. https://doi.org/10.1056/NEJMoa1616218
[21]
Landoni, G., Lomivorotov, V.V., Alvaro, G., et al. (2017) Levosimendan for Hemodynamic Support after Cardiac Surgery. New England Journal of Medicine, 376, 2021-2031. https://doi.org/10.1056/NEJMoa1616325
[22]
Cholley, B., Caruba, T., Grosjean, S., Amour, J., Ouattara, A., Villacorta, J., Miguet, B., Guinet, P., Lévy, F., Squara, P., Aït Hamou, N., Carillon, A., Boyer, J., Boughenou, M., Rosier, S., Robin, E., Radutoiu, M., Durand, M., Guidon, C., Desebbe, O., Charles-Nelson, A., Menasché, P., Rozec, B., Girard, C., Fellahi, J., Pirracchio, R. and Chatellier, G. (2017) Effect of Levosimendan on Low Cardiac Output Syndrome in Patients with Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting with Cardiopulmonary Bypass the Licorn Randomized Clinical Trial. JAMA, 318, 548-556. https://doi.org/10.1001/jama.2017.9973
